PNCA3
MCID: PNC095
MIFTS: 22

Pancreatic Cancer 3 (PNCA3)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pancreatic Cancer 3

MalaCards integrated aliases for Pancreatic Cancer 3:

Name: Pancreatic Cancer 3 57 73 29 6
Pancreatic Cancer, Susceptibility to, 3 57 13
Pnca3 57 73
Cancer, Pancreatic, Susceptibility to, Type 3 39

Classifications:



External Ids:

OMIM® 57 613348
MeSH 44 D010190
MedGen 41 C3150547

Summaries for Pancreatic Cancer 3

UniProtKB/Swiss-Prot : 73 Pancreatic cancer 3: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 3, is also known as pancreatic cancer, susceptibility to, 3. An important gene associated with Pancreatic Cancer 3 is PALB2 (Partner And Localizer Of BRCA2). Affiliated tissues include pancreas, liver and breast.

More information from OMIM: 613348

Related Diseases for Pancreatic Cancer 3

Symptoms & Phenotypes for Pancreatic Cancer 3

Clinical features from OMIM®:

613348 (Updated 05-Mar-2021)

Drugs & Therapeutics for Pancreatic Cancer 3

Search Clinical Trials , NIH Clinical Center for Pancreatic Cancer 3

Genetic Tests for Pancreatic Cancer 3

Genetic tests related to Pancreatic Cancer 3:

# Genetic test Affiliating Genes
1 Pancreatic Cancer 3 29 PALB2

Anatomical Context for Pancreatic Cancer 3

MalaCards organs/tissues related to Pancreatic Cancer 3:

40
Pancreas, Liver, Breast

Publications for Pancreatic Cancer 3

Articles related to Pancreatic Cancer 3:

(show all 22)
# Title Authors PMID Year
1
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. 57 6
19264984 2009
2
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 57
25356972 2015
3
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. 57
17200668 2007
4
Is There any Survival Benefit of Maintenance Chemotherapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer Patients with Post-Surgery Elevated CA 19-9? 61
32982620 2020
5
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. 61
30306620 2019
6
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. 61
31230047 2019
7
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. 61
27893535 2018
8
Inferoposterior duodenal approach for laparoscopic pancreaticoduodenectomy. 61
26877619 2016
9
Inferior vena caval thrombosis complicating pyogenic liver abscess after pancreatoduodenectomy: a case report. 61
26380170 2015
10
Long-term outcomes after hepatic resection combined with radiofrequency ablation for initially unresectable multiple and bilobar liver malignancies. 61
24387841 2014
11
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. 61
24419109 2014
12
Vitamin D status and the risk of pancreatic cancer: a meta-analysis. 61
24033964 2013
13
Study on chronic pancreatitis and pancreatic cancer using MRS and pancreatic juice samples. 61
21547133 2011
14
Adjuvant therapy of pancreatic cancer. 61
20397913 2010
15
Diagnosis of pancreatic cancer by cytology and telomerase activity in exfoliated cells obtained by pancreatic duct brushing during endoscopy. 61
17548257 2007
16
Serum IgG4 concentrations in pancreatic and biliary diseases. 61
16426597 2006
17
Mangan-enhanced MR imaging for the detection and localisation of small pancreatic insulinoma. 61
12955450 2004
18
Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. 61
15039161 2004
19
Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report. 61
14576500 2003
20
Magnetic resonance study of the pancreatic duct. 61
10348928 1999
21
[Acute cholecystitis after placement of biliary endoprosthesis. Treatment by percutaneous cholecystostomy]. 61
2966350 1988
22
Diagnostic significance of bile cytology in obstructive jaundice. 61
6748391 1984

Variations for Pancreatic Cancer 3

ClinVar genetic disease variations for Pancreatic Cancer 3:

6 (show all 47)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PALB2 NM_024675.3(PALB2):c.3256C>T (p.Arg1086Ter) SNV Pathogenic, risk factor 126729 rs587776527 16:23619279-23619279 16:23607958-23607958
2 PALB2 NM_024675.4(PALB2):c.1240C>T (p.Arg414Ter) SNV Pathogenic 128117 rs180177100 16:23646627-23646627 16:23635306-23635306
3 PALB2 NM_024675.3(PALB2):c.3549C>A (p.Tyr1183Ter) SNV Pathogenic 128144 rs118203998 16:23614792-23614792 16:23603471-23603471
4 PALB2 NM_024675.3(PALB2):c.3549C>A (p.Tyr1183Ter) SNV Pathogenic 128144 rs118203998 16:23614792-23614792 16:23603471-23603471
5 PALB2 NM_024675.3(PALB2):c.106C>T (p.Gln36Ter) SNV Pathogenic 402288 rs757369748 16:23649393-23649393 16:23638072-23638072
6 PALB2 NM_024675.3(PALB2):c.2509G>T (p.Glu837Ter) SNV Pathogenic 241546 rs587778587 16:23640966-23640966 16:23629645-23629645
7 PALB2 NM_024675.3(PALB2):c.2120del (p.Pro707fs) Deletion Pathogenic 128128 rs587780210 16:23641355-23641355 16:23630034-23630034
8 PALB2 NM_024675.4(PALB2):c.509_510del Deletion Pathogenic 126757 rs515726123 16:23647357-23647358 16:23636036-23636037
9 PALB2 NM_024675.3(PALB2):c.226del (p.Ile76fs) Deletion Pathogenic 142408 rs587782443 16:23647641-23647641 16:23636320-23636320
10 PALB2 NM_024675.3(PALB2):c.2834+1G>T SNV Pathogenic 143968 rs587776419 16:23635329-23635329 16:23624008-23624008
11 PALB2 NM_024675.3(PALB2):c.2515-1G>A SNV Likely pathogenic 582926 rs587776417 16:23640597-23640597 16:23629276-23629276
12 PALB2 NM_024675.4(PALB2):c.108+1G>A SNV Likely pathogenic 402289 rs1060499814 16:23649390-23649390 16:23638069-23638069
13 PALB2 NM_024675.3(PALB2):c.3116del (p.Asn1039fs) Deletion risk factor 126715 rs180177133 16:23625410-23625410 16:23614089-23614089
14 PALB2 NM_024675.4(PALB2):c.2974_2975del (p.Met992fs) Deletion Likely pathogenic 979078 16:23634311-23634312 16:23622990-23622991
15 PALB2 PALB2:c.2515-1G>T SNV risk factor 126657 rs587776417 16:23640597-23640597 16:23629276-23629276
16 PALB2 NM_024675.4(PALB2):c.168_171TTGT[1] (p.Gln60fs) Microsatellite risk factor 126623 rs180177143 16:23649207-23649210 16:23637886-23637889
17 PALB2 NM_024675.4(PALB2):c.1299G>T (p.Leu433Phe) SNV Uncertain significance 979137 16:23646568-23646568 16:23635247-23635247
18 PALB2 NM_024675.3(PALB2):c.2641G>A (p.Gly881Ser) SNV Uncertain significance 460951 rs766315705 16:23637664-23637664 16:23626343-23626343
19 PALB2 NM_024675.3(PALB2):c.2660T>G (p.Ile887Ser) SNV Uncertain significance 484201 rs45550935 16:23637645-23637645 16:23626324-23626324
20 PALB2 NM_024675.3(PALB2):c.3025C>T (p.Pro1009Ser) SNV Uncertain significance 419928 rs764669864 16:23632771-23632771 16:23621450-23621450
21 PALB2 NM_024675.3(PALB2):c.3054G>T (p.Glu1018Asp) SNV Uncertain significance 420826 rs183489969 16:23632742-23632742 16:23621421-23621421
22 PALB2 NM_024675.3(PALB2):c.11C>T (p.Pro4Leu) SNV Uncertain significance 126593 rs45619737 16:23652468-23652468 16:23641147-23641147
23 PALB2 NM_024675.3(PALB2):c.2773G>C (p.Val925Leu) SNV Uncertain significance 126681 rs180177125 16:23635391-23635391 16:23624070-23624070
24 PALB2 NM_024675.3(PALB2):c.3307G>C (p.Val1103Leu) SNV Uncertain significance 141974 rs201657283 16:23619228-23619228 16:23607907-23607907
25 PALB2 NM_024675.3(PALB2):c.3251C>T (p.Ser1084Leu) SNV Uncertain significance 126727 rs62625271 16:23619284-23619284 16:23607963-23607963
26 PALB2 NM_024675.3(PALB2):c.3247G>A (p.Glu1083Lys) SNV Uncertain significance 216753 rs747785029 16:23619288-23619288 16:23607967-23607967
27 PALB2 NM_024675.4(PALB2):c.2897T>C (p.Ile966Thr) SNV Uncertain significance 128136 rs587780214 16:23634389-23634389 16:23623068-23623068
28 PALB2 NM_024675.4(PALB2):c.2869A>C (p.Lys957Gln) SNV Uncertain significance 126694 rs515726103 16:23634417-23634417 16:23623096-23623096
29 PALB2 NM_024675.3(PALB2):c.2473A>G (p.Arg825Gly) SNV Uncertain significance 402299 rs745747228 16:23641002-23641002 16:23629681-23629681
30 PALB2 NM_024675.3(PALB2):c.2026A>C (p.Ile676Leu) SNV Uncertain significance 484244 rs761478794 16:23641449-23641449 16:23630128-23630128
31 PALB2 NM_024675.3(PALB2):c.1759G>A (p.Ala587Thr) SNV Uncertain significance 410106 rs1060502733 16:23641716-23641716 16:23630395-23630395
32 PALB2 NM_024675.3(PALB2):c.1756G>A (p.Asp586Asn) SNV Uncertain significance 141709 rs587781954 16:23641719-23641719 16:23630398-23630398
33 PALB2 NM_024675.3(PALB2):c.1526G>A (p.Gly509Asp) SNV Uncertain significance 186732 rs786203176 16:23646341-23646341 16:23635020-23635020
34 PALB2 NM_024675.3(PALB2):c.1348A>C (p.Asn450His) SNV Uncertain significance 128119 rs62625274 16:23646519-23646519 16:23635198-23635198
35 PALB2 NM_024675.3(PALB2):c.1340C>A (p.Ala447Glu) SNV Uncertain significance 480285 rs1555461334 16:23646527-23646527 16:23635206-23635206
36 PALB2 NM_024675.3(PALB2):c.1316G>T (p.Gly439Val) SNV Uncertain significance 188096 rs537258442 16:23646551-23646551 16:23635230-23635230
37 PALB2 NM_024675.3(PALB2):c.1115G>C (p.Ser372Thr) SNV Uncertain significance 188377 rs786204243 16:23646752-23646752 16:23635431-23635431
38 PALB2 NM_024675.3(PALB2):c.968C>A (p.Ala323Glu) SNV Uncertain significance 182760 rs730881882 16:23646899-23646899 16:23635578-23635578
39 PALB2 NM_024675.3(PALB2):c.187C>T (p.Leu63Phe) SNV Uncertain significance 182780 rs730881899 16:23649195-23649195 16:23637874-23637874
40 PALB2 NM_024675.4(PALB2):c.194C>T (p.Pro65Leu) SNV Uncertain significance 128124 rs62625272 16:23649188-23649188 16:23637867-23637867
41 PALB2 NM_024675.3(PALB2):c.1222T>C (p.Tyr408His) SNV Uncertain significance 126594 rs515726064 16:23646645-23646645 16:23635324-23635324
42 PALB2 NM_024675.3(PALB2):c.1732A>G (p.Ser578Gly) SNV Uncertain significance 229738 rs764023822 16:23641743-23641743 16:23630422-23630422
43 PALB2 NM_024675.3(PALB2):c.2417C>T (p.Pro806Leu) SNV Uncertain significance 141063 rs45464991 16:23641058-23641058 16:23629737-23629737
44 PALB2 NM_024675.3(PALB2):c.3428T>C (p.Leu1143Pro) SNV Uncertain significance 126741 rs62625284 16:23614913-23614913 16:23603592-23603592
45 PALB2 NM_024675.4(PALB2):c.3428T>A (p.Leu1143His) SNV Uncertain significance 126740 rs62625284 16:23614913-23614913 16:23603592-23603592
46 PALB2 NM_024675.3(PALB2):c.2773G>C (p.Val925Leu) SNV Uncertain significance 126681 rs180177125 16:23635391-23635391 16:23624070-23624070
47 PALB2 NM_024675.4(PALB2):c.1540G>A (p.Gly514Arg) SNV Uncertain significance 232748 rs756778249 16:23646327-23646327 16:23635006-23635006

Expression for Pancreatic Cancer 3

Search GEO for disease gene expression data for Pancreatic Cancer 3.

Pathways for Pancreatic Cancer 3

GO Terms for Pancreatic Cancer 3

Sources for Pancreatic Cancer 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....